Of all viral upper respiratory infections, infectious mononucleosis (IM) presents the greatest challenge for return to play of the athlete because of the concern for splenic rupture. Diagnosis and appropriate evaluation of the athlete is important to reduce the risk of splenic rupture. When IM is suspected, removal from participation and referral for proper clinical evaluation is essential to prevent morbidity and mortality. Recognition of the signs and symptoms of splenic rupture is critical for acute management of this potentially catastrophic injury. IM is a self-limiting illness that is most commonly seen in adolescents and young adults, 1 with 1 to 3% of college students becoming infected annually. 2 It is most commonly caused by the Epstein-Bar virus (EBV), which is part of the herpes virus family. EBV is usually spread by direct contact with saliva, hence it has been labeled "the kissing disease." Most cases of IM resolve without sequelae, but several acute complications are associated with this disease. Splenic rupture generally occurs in the first 3 weeks of the illness. 3 Thus, timing of the illness is essential in determination of return to play. 
Clinical Presentation
Symptoms are usually less severe in adolescents and young adults than in older adults. Sore throat, fever, and lymphadenopathy are often referred to as the classic triad of IM, 4 but the most common symptoms are sore throat and fatigue. Prodromal symptoms of headache, fatigue (often severe), anorexia, and myalgia often precede the classic symptoms by 3-5 days. 5 Other signs and symptoms of IM include splenomegaly, abdominal pain, a decline in exercise tolerance, palatial petechia, rash on the trunk and abdomen (especially if treated with ampicillin or amoxicillin), and jaundice (Table 1) . Physical examination for identification of splenomegaly has poor sensitivity and specificity, which will exist in at least 50% of IM cases. 6 Symptoms and laboratory findings usually resolve within 4 weeks, but lymphadenopathy and fatigue can persist longer. 4 The severity of symptoms can vary significantly. Among individuals who are immune-compromised, the symptoms are often severe. 6 Splenic rupture is rare, which has been reported to have an incidence of 0.1-0.2%. 6 It is important to note that splenic rupture can occur spontaneously or as a result of trauma. Symptoms of new or increasing abdominal pain, sudden onset of left shoulder pain, and symptoms of hypovolemia, such as dizziness or lightheadedness, should raise suspicion for splenic rupture, especially in an athlete with current or recent upper respiratory symptoms. 7 
Diagnosis
Clinical presentation of IM can be very similar to other causes of viral or bacterial pharyngitis. It is especially important to differentiate between group A, streptococcal pharyngitis, and IM, because antibiotics are only needed for the former condition. Commonly used β-lactam antibiotics, such as amoxicillin, can produce a morbilliform rash in up to 95% of patients with IM; 4 however, approximately 25% of individuals with IM will also have Group A streptococcal pharyngitis. 8 Rapid antigen testing and a throat swab could be used to help establish the diagnosis of bacterial pharyngitis.
Commonly used screening tests for IM are a "monospot" test and differential blood count, which reveal marked lymphocytosis (> 50%) with at least 10% atypical lymphocytes. In the presence of IM symptoms, a positive monospot test has a sensitivity of approximately 85% and specificity of approximately 94%. 4 The monospot test may be falsely negative early in the progression of the disorder in young children (< 12 years) and in the elderly population. It may be falsely positive in people with connective tissue disease, viral hepatitis, systemic lupus erythematosus, malaria, or immune-compromised individuals. Thus, if initial testing is negative, repeat testing in 2-3 weeks may be necessary to make the diagnosis (Table 2) . Confirmation through specific antibody testing may be necessary (Table 3 ). The current literature does not support the routine use of liver function tests or abdominal ultrasound in IM patients. 6, 8, 9 There is no definitive evidence to suggest that either of these tests could establish a prognosis or aid in return to play decisions. The use of abdominal ultrasound to assess spleen size is controversial due to variability of spleen size and shape in healthy individuals. 9, 10 Moreover, many 
Management
The mainstay of treatment is symptomatic management of sore throat and fever with acetaminophen or other non-steroidal anti-inflammatory agents, along with adequate hydration and rest. Hepatotoxic agents like alcohol and aspirin should be avoided. Because the majority of the population is EBV sero-positive, no special precaution for preventing transmission is recommended. 4 Corticosteroids and antiviral agents, such as like acyclovir and valacyclovir, have sometimes been used to treat IM, but the literature does not definitively support any benefit. Corticosteroid therapy may have some role in treating tonsillar enlargement that causes oropharyngeal obstruction. Such therapy, however, may predispose patients to superimposed bacterial infections. Efforts are currently underway to develop a vaccine for EBV.
Return to Play
It is important to individualize the timeframe for return to play of any athlete with IM. The risk of splenic rupture is greatest within the first 3 weeks from the onset of symptoms. This risk is due to increased spleen size and altered splenic architecture. Splenic rupture can result from any kind of physical exertion, including a simple Valsalva maneuver. Therefore, "flak jackets" would provide no benefit for prevention of splenic rupture. Current consensus guidelines recommend avoidance of contact or noncontact physical activity within first three weeks after onset of symptoms. 6 In addition, the athlete should be afebrile with resolution of symptoms and should feel well enough to play. If these criteria are met, gradual light noncontact activity may be started at 3 weeks after symptom onset. If the time of onset of IM is unclear, EBV titers can be useful. If Epstein-Barr virus nuclear antigen (EBNA) is present, it usually indicates that the athlete has had IM for at least 6-8 weeks. If the EBV titers are equivocal, the safe option is timing the start of the illness from the presentation of symptoms. If the athlete is progressing well, contact activity may be initiated within the next 1-2 weeks. Abrupt progression of physical activity should be avoided. It is important to note that the risk of splenic rupture is never zero, but it declines over time. 6 Certain sports, such as weightlifting, may present high risk (due to sudden rise in intraabdominal pressure) and warrant prolonged restriction from sportrelated activity. Physical examination and radiologic images have been unreliable in assessing the risk of splenic rupture in return to play decisions. 6, 9 Education of the athlete and parents is an important aspect of any return-to-play protocol.
Summary
IM is a common illness among young, active individuals. Recognizing the signs and symptoms of IM and removal from participation in exercise is important until thorough evaluation is completed. Although splenic rupture is the most serious complication, it is rare and most often occurs within the first 3 weeks of the illness. Therefore, determination that splenomegaly exists is not necessary. Most athletes with IM have symptoms that make it difficult for them to participate sooner than 3-4 weeks. Return to light activity should not occur sooner than 3 weeks and then, only if afebrile and having minimal symptoms. Return to contact can be permitted after progressing from light activity and once all signs and symptoms have resolved (typically no sooner than 4 weeks). 6 Recognition of splenic rupture for immediate emergency management is critical.  
